| DC Field | Value | Language |
|---|
| dc.contributor.author | Belyaeva, V. S. | - |
| dc.contributor.author | Stepenko, Yu. V. | - |
| dc.contributor.author | Kulikov, A. L. | - |
| dc.contributor.author | Kochkarova, I. S. | - |
| dc.contributor.author | Martynova, O. V. | - |
| dc.contributor.author | Pokrovskiy, M. V. | - |
| dc.date.accessioned | 2021-06-29T13:20:46Z | - |
| dc.date.available | 2021-06-29T13:20:46Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.citation | Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases / V.S. Belyaeva [et al.] // Research Results in Pharmacology. - 2020. - Vol.6, №3.-P. 75-86. - Doi: 10.3897/rrpharmacology.6.58891. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/42565 | - |
| dc.description.abstract | Research in recent decades has shown that erythropoietin has a high cytoprotective activity, which is mainly associated with exposure to the mitochondrial link and has been confirmed in various experimental models. There is also a short-chain derivative, the 11-amino acid pyroglutamate helix B surface peptide (PHBSP), which selectively binds to the erythropoietin heterodymic receptor and reproduces its cytoprotective properties. This indicates the promising use of short-chain derivatives of erythropoietin for the treatment and prevention of atherosclerotic vascular injury | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | atherosclerosis | ru |
| dc.subject | cytoprotection | ru |
| dc.subject | erythropoietin | ru |
| dc.subject | cardiovascular diseases | ru |
| dc.subject | peptides | ru |
| dc.title | Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases | ru |
| dc.type | Article | ru |
| Appears in Collections: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)
|
